Rallybio Corp
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
RLYB$15.76+0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets
| (in thousands, except share and per share amounts) | SEPTEMBER 30,2024 | DECEMBER 31,2023 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $25,320 | $24,494 |
| Marketable securities | 49,819 | 85,435 |
| Prepaid expenses and other current assets | 3,091 | 4,860 |
| Total current assets | 78,230 | 114,789 |
| Property and equipment, net | 145 | 246 |
| Operating lease right-of-use assets | 201 | 346 |
| Investment in joint venture | 431 | 239 |
| Total assets | $79,007 | $115,620 |
| Liabilities and stockholders' equity | ||
| Current liabilities: | ||
| Accounts payable | $583 | $976 |
| Accrued expenses | 6,279 | 8,068 |
| Operating lease liabilities | 230 | 219 |
| Deferred revenue | 1,097 | — |
| Total current liabilities | 8,189 | 9,263 |
| Operating lease liabilities, noncurrent | — | 173 |
| Total liabilities | 8,189 | 9,436 |
| Commitments and contingencies (Note 7) | ||
| Stockholders' equity | ||
| Common stock, $0.0001 par value per share; 200,000,000 shares authorized as of September 30, 2024 and December 31, 2023, respectively; and 41,487,586 and 37,829,565 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively | 4 | 4 |
| Preferred stock, $0.0001 par value per share; 50,000,000 shares authorized as of September 30, 2024 and December 31, 2023, respectively; no shares issued or outstanding as of September 30, 2024 and December 31, 2023, respectively | — | — |
| Additional paid-in capital | 352,621 | 341,410 |
| Accumulated other comprehensive loss | 169 | 15 |
| Accumulated deficit | (281,976) | (235,245) |
| Total stockholders' equity | 70,818 | 106,184 |
| Total liabilities and stockholders' equity | $79,007 | $115,620 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.